Gen1E is a drug development company. Gen1E has an AI platform to screen for treatments of rare inflammatory diseases such as ARDS, ALS, Cystic Fibrosis. The CEO has been working on the p38 pathway which is the key driver of inflammation at a number of companies over the past 20 years. The Company has 21 compounds in their pipeline, with matching indications. Currently, Gen1E has cleared Phase I with its lead compound to treat ARDS, the leading cause of death related to Covid 19 infections.